Century Therapeutics (IPSC) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Lexeo Therapeutics (LXEO) over the past year, gaining 150.0% versus a loss of 60.0%. Century Therapeutics is the larger company by market cap ($264.4 million vs $263.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | LXEO |
|---|---|---|
| Share price | $1.46 | $3.21 |
| Market cap | $264.37M | $263.50M |
| 1-day change | +14.06% | -3.02% |
| YTD return | +46.73% | -67.67% |
| 1-year return | +150.00% | -60.02% |
| 5-year return | -92.44% | — |
| EPS (TTM) | $-0.93 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $10.99 |
| 52-week low | $0.435 | $2.98 |
| Distance from 52-week high | -51.97% | -70.79% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +225.34% | +532.40% |
| Average volume | 649.61K | 1.20M |
| Shares outstanding | 181.08M | 82.09M |
| Employees | 78 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed LXEO by 210.0 percentage points over the past year.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
IPSC vs LXEO FAQ
Which is bigger, Century Therapeutics or Lexeo Therapeutics?
Century Therapeutics (IPSC) is larger, with a market capitalization of $264.37M compared with $263.50M for Lexeo Therapeutics (LXEO).
Which stock has performed better over the past year, IPSC or LXEO?
IPSC returned +150.00% over the past 12 months, compared with -60.02% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.